WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2017178577) MEDICAL APPLICATION OF RESMINOSTAT IN ASIAN PATIENTS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2017/178577    International Application No.:    PCT/EP2017/058902
Publication Date: 19.10.2017 International Filing Date: 13.04.2017
IPC:
A61K 45/06 (2006.01), A61K 31/40 (2006.01), A61P 35/00 (2006.01), A61K 31/44 (2006.01)
Applicants: 4SC AG [DE/DE]; Fraunhoferstraße 22 82152 Planegg-Martinsried (DE)
Inventors: GRÖPPEL, Manfred; (DE)
Agent: BOEHMERT & BOEHMERT; Hollerallee 32 28209 Bremen (DE)
Priority Data:
16165258.1 14.04.2016 EP
Title (EN) MEDICAL APPLICATION OF RESMINOSTAT IN ASIAN PATIENTS
(FR) APPLICATION MÉDICALE DE RESMINOSTAT CHEZ DES PATIENTS ASIATIQUES
Abstract: front page image
(EN)The invention relates to medical applications of the HDAC inhibitor resminostat ((E)-3-[1-{4-Dimethylaminomethyl-benzenesulfonyl)-1H-pyrroi-3-yl]-N-hydroxy-acrylamide) or a salt or solvate thereof in the treatment of benign or malignant neoplasia in a human subject, wherein said human subject is an Asian, and wherein said treatment comprises administering resminostat or a salt or solvate thereof to said human subiect in a daily dose of less than 600 mg resminostat, and administering at least one further chemotherapeutic agent to said human subject.
(FR)L'invention concerne des applications médicales de l'inhibiteur de HDAC resminostat ((E)-3-[1- {4-diméthylaminométhyl-benzènesulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide) ou un sel ou un solvate de ce dernier dans le traitement d'une néoplasie bénigne ou maligne chez un sujet humain, ledit sujet humain étant un sujet asiatique, et ledit traitement comprenant l'administration de resminostat ou d'un sel ou d'un solvate de ce dernier audit sujet humain à une dose quotidienne inférieure à 600 mg de resminostat, et l'administration d'au moins un autre agent chimiothérapeutique audit sujet humain.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)